News | February 17, 2025
Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
No safety signals related to the vaccine candidate were identified
No safety signals related to the vaccine candidate were identified
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
He has over 23 years of experience across sectors
Plans underway to expand screening capacity by 50% for greater accessibility
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
The company remains focused on strengthening its direct retail presence and expanding its reach to more customers across India.
Subscribe To Our Newsletter & Stay Updated
